Evidence map›Paper›PMID 34852237›Full record

ArticleCell2021

A defective viral genome strategy elicits broad protective immunity against respiratory viruses.

Yinghong Xiao, Peter V Lidsky, Yuta Shirogane, Ranen Aviner, Chien-Ting Wu, Weiyi Li, Weihao Zheng, Dale Talbot, Adam Catching, Gilad Doitsh and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 4 countries.

Yinghong XiaoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Peter V LidskyDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Yuta ShiroganeDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Ranen AvinerDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Biology and Genetics, Stanford University, Stanford, CA 94305, USA.
Chien-Ting WuBaxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University, Stanford, CA 94305, USA.
Weiyi LiDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Weihao ZhengDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Dale TalbotDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Aleph Therapeutics, Inc., Stanford, CA 94305, USA.
Adam CatchingDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Gilad DoitshDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Weiheng SuDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; School of Life Sciences, Jilin University, Changchun, China.
Colby E GekkoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA.
Arabinda NayakDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Biology and Genetics, Stanford University, Stanford, CA 94305, USA.
Joel D ErnstDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Leonid BrodskyTauber Bioinformatics Research Center and Department of Evolutionary & Environmental Biology, University of Haifa, Mount Carmel, Haifa 31905, Israel.
Elia BrodskyPine Biotech Inc., New Orleans, LA 70112, USA.
Elsa RousseauFunctional Genomics and Cellular Engineering, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA 95120, USA.
Sara CapponiFunctional Genomics and Cellular Engineering, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA 95120, USA.
Simone BiancoFunctional Genomics and Cellular Engineering, AI and Cognitive Software, IBM Almaden Research Center, San Jose, CA 95120, USA.
Robert NakamuraAleph Therapeutics, Inc., Stanford, CA 94305, USA.
Peter K JacksonBaxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University, Stanford, CA 94305, USA.
Judith FrydmanDepartment of Biology and Genetics, Stanford University, Stanford, CA 94305, USA.
Raul AndinoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: raul.andino@ucsf.edu.
University of California, San Francisco · USIBM Research - Almaden · USStanford University · USCook Biotech (United States) · USKyushu University · JPUniversity of Haifa · IL

Funding

Unbiased Functional Characterization of Enterovirus-Host InteractionsP01AI091575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 2011 to 2015
$10.5M
RNA PROTEIN INTERACTIONS IN POLIOVIRUS REPLICATIONR01AI040085 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 1998 to 2019
$5.8M
Mapping spatiotemporal dynamics during enterovirus infection across cells and tissuesR01AI169460 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Raul Andino, Luis J Sigal · 2022 to 2026
$4.5M
RECOMBINANT PICORNAVIRUSES AS AIDS VACCINESR01AI036178 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 1994 to 2011
$3.6M
Defining the role of Host Hsp70 Subnetworks in Dengue Virus ReplicationR01AI127447 · NIAID · STANFORD UNIVERSITY · PI FRYDMAN, JUDITH · 2017 to 2021
$2.4M
Targeting Covid-19 with a Therapeutic Interfering ParticleR41AI157129 · NIAID · ALEPH THERAPEUTICS, INC. · PI ANDINO, RAUL · 2021 to 2022
$596k
Genetic Diversity as a determinant of viral adaptation and pathogenesisR56AI036178 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 2014 to 2014
$531k
EV71 intra-host evolution, attenuation and vaccine developmentR21AI144144 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDINO, RAUL · 2019 to 2020
$442k
A Vaccine for Acute Flaccid MyelitisR41AI155100 · NIAID · ALEPH THERAPEUTICS, INC. · PI ANDINO, RAUL · 2020 to 2020
$250k
NIAID NIH HHS P01 AI091575NIAID NIH HHS R01 AI036178NIAID NIH HHS R01 AI040085NIAID NIH HHS R01 AI127447NIAID NIH HHS R01 AI169460NIAID NIH HHS R21 AI144144NIAID NIH HHS R41 AI155100NIAID NIH HHS R41 AI157129NIAID NIH HHS R56 AI036178
6 · The paper itself

Abstract

RNA viruses generate defective viral genomes (DVGs) that can interfere with replication of the parental wild-type virus. To examine their therapeutic potential, we created a DVG by deleting the capsid-coding region of poliovirus. Strikingly, intraperitoneal or intranasal administration of this genome, which we termed eTIP1, elicits an antiviral response, inhibits replication, and protects mice from several RNA viruses, including enteroviruses, influenza, and SARS-CoV-2. While eTIP1 replication following intranasal administration is limited to the nasal cavity, its antiviral action extends non-cell-autonomously to the lungs. eTIP1 broad-spectrum antiviral effects are mediated by both local and distal type I interferon responses. Importantly, while a single eTIP1 dose protects animals from SARS-CoV-2 infection, it also stimulates production of SARS-CoV-2 neutralizing antibodies that afford long-lasting protection from SARS-CoV-2 reinfection. Thus, eTIP1 is a safe and effective broad-spectrum antiviral generating short- and long-term protection against SARS-CoV-2 and other respiratory infections in animal models.

Indexed as

Administration, IntranasalAnimalsAntiviral AgentsBroadly Neutralizing AntibodiesCapsid ProteinsCell LineCOVID-19Defective Interfering VirusesDisease Models, AnimalGenome, ViralHumansInfluenza, HumanInterferonsMaleMiceMice, Inbred C57BLAntiviral AgentsBroadly Neutralizing AntibodiesCapsid ProteinsInterferonsantiviralbroad-spectrumdefective viral genomesinnate immunityinterferonrespiratory infectionRNA virusesSARS-CoV-2

Identifiers

PMID34852237
PMCPMC8598942
OpenAlexW3214039811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.